Keyword: Sequoia Capital

IDG Capital led the round with the support of a clutch of other existing and new investors, including Gilead’s CAR-T unit Kite.

GenEdit raised $8.5 million to develop its proprietary polymer nanoparticle system for the delivery of gene therapy and gene editing.

RootPath raised $7 million to develop a T-cell therapy platform for cancer treatment that addresses the shortcomings of current technology.

Brii Biosciences' mission is to overcome the challenges that have prevented the spread of innovative medicines throughout China.

Grail has gone 3-for-3 in venture capital rounds topping $100 million—with a $300 million addition bringing its total up to $1.5 billion since 2016.

Refuge's platform generates cells "that are programmed to make cancer-fighting decisions inside the patient's body." 

The Sino-American startup thinks it can detect cell-free DNA in blood plasma and thereby enable screening for early-stage disease.

The investment positions the Chinese antibody discovery shop to move the most advanced assets in its oncology pipeline into human testing.

The genetic diagnostics business will use the cash to increase access to its tests outside of India’s biggest cities.

XtalPi combines AI, quantum physics and cloud computing to predict drugs’ crystal structures more quickly and accurately.